Clinical Trial Update: HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 [Phase 2]

View source ↗

Summary

A Phase II study evaluating two doses of GT005 for dry age-related macular degeneration was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Age-related Macular Degeneration

Drugs mentioned

• GT005

Snippet

Sponsor: Gyroscope Therapeutics Limited | Conditions: Dry Age-related Macular Degeneration | Phase 2 | Status: TERMINATED | Results posted: 2025-07-10